Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Innovation Mindsets To Incentives And COVID-19 Lessons: How EU Pharma Legislation Should Evolve

Executive Summary

If the EU wants to become a more competitive space for innovation it can take a few lessons from both the US and the COVID-10 pandemic, say European pharma industry representatives. Fostering better communication between regulators and companies is just one example.

You may also be interested in...



Improving Medicines Availability Tops EU Regulators’ 2025 Workplan

The coordination group for EU mutual recognition and decentralized procedures is inviting stakeholder feedback on its priorities for the coming years.

European Industry Proposes Incentive To Develop New Antimicrobials

With proposals for an overhaul of the EU medicines legislation due at the end of this year, EFPIA has published its formal response to the European Commission’s consultation with suggestions for facilitating new antibiotic development, testing new regulatory approaches to novel medicines, and tackling medicine shortages.

EU Actions ‘Will Weaken IP And Undermine Innovation’

In its 2022 “Special 301” submission, US pharmaceutical industry group PhRMA says that EU data protections and other incentives for innovative R&D are under threat, echoing concerns already expressed by European industry bodies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel